2026-02-12, 2:32:13 p.m.
TORONTO, ON — February 12, 2026 — Leads & Copy — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) will release its financial results for the fourth quarter and full year 2025 after the market closes on Thursday, March 5, 2026. The company is a commercial-stage medical device company specializing in innovative interventional MRI (iMRI) procedures.
Profound’s management team will host a conference call at 4:30 p.m. ET to discuss the financial results and provide updates on business developments during the period.
Details for the conference call are as follows:
The conference call is scheduled for Thursday, March 5, 2026, at 4:30 p.m. ET. To register for the live call, visit: https://register-conf.media-server.com/register/BI9b6f3d29fd3749db83543442274147c2.
The conference call will be broadcast live on the company’s website and archived in the Investors section.
Profound is focused on commercializing TULSA-PRO®, a technology combining real-time MRI, AI-enhanced planning, robotically-driven transurethral ultrasound, and closed-loop temperature feedback control. The TULSA Procedure™, performed using the TULSA-PRO system, is a treatment modality for prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (“BPH”); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer.
The TULSA Procedure employs real-time MR guidance for precision to preserve patients’ urinary continence and sexual function, while killing the targeted prostate tissue via precise sound absorption technology that gently heats it to 55-57°C. The TULSA Procedure is an incision- and radiation-free “one-and-done” procedure performed in a single session that takes a few hours. Virtually all prostate shapes and sizes can be safely, effectively, and efficiently treated with the TULSA Procedure. There is no bleeding associated with the procedure; no hospital stay is required; and most TULSA patients report quick recovery to their normal routine. TULSA-PRO is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (“FDA”).
The company is also commercializing Sonalleve®, a therapeutic platform that is CE marked for the treatment of uterine fibroids, adenomyosis, pain palliation of bone metastases, desmoid tumors and osteoid osteoma. Sonalleve has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma. Profound is exploring additional potential treatment markets for Sonalleve such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.
Source: Profound Medical Corp.
